<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340040</url>
  </required_header>
  <id_info>
    <org_study_id>D5621C00006</org_study_id>
    <nct_id>NCT01340040</nct_id>
  </id_info>
  <brief_title>Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects</brief_title>
  <official_title>A Phase 1, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-573, a Fully Human Monoclonal Antibody Directed Against Insulin-like Growth Factors I and II, in Japanese Subjects With Advanced Solid Tumours Refractory to Standard Therapy or for Which No Standard Therapy Exists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to explore the safety and tolerability of MEDI-573 in
      Japanese subjects with advanced solid tumours refractory to standard therapy or for which no
      standard therapy exists.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (based on CTCAE version 4.0), laboratory values, vital sign measurements, ECG, Physical Examination</measure>
    <time_frame>All AEs will be collected throughout the study, from informed consent until 30 days after the end of study treatment.</time_frame>
    <description>The total duration of this time frame can not be specified, as it depends on the number of treatments the subject may receive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of MEDI-573 (by measuring anti-MEDI-573 antibodies)</measure>
    <time_frame>For Cohorts 1, 2 and 3:day 1 (pre-dose) of every cycle; 30 days after the last dose; 3 months after the last dose</time_frame>
    <description>The total duration of this time frame can not be specified, as it depends on the number of treatments the subject may receive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of MEDI-573 using Response Evaluation Criteria in Solid Tumors(RECIST)</measure>
    <time_frame>Tumor assessment by RECIST 1.1 every 2 cycles</time_frame>
    <description>subjects who discontinue the study treatment for reasons other than disease progression or initiation of alternative anticancer therapy will undergo tumor assessment 3 months after the last dose of MEDI-573). The total duration of this time frame can not be specified, as it depends on the number of treatments the subject may receive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, - Cmax</measure>
    <time_frame>For Cohorts 1, 2 and 3:Multiple timepoints taken, begining at Day 1 and until 30 days after last dose.</time_frame>
    <description>The total duration of this time frame can not be specified, as it depends on the number of treatments the subject may receive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics,- Cmax at steady state (Cmax, ss)</measure>
    <time_frame>For Cohorts 1, 2 and 3: Multiple timepoints taken, begining at Day 1 and until 30 days after last dose.</time_frame>
    <description>The total duration of this time frame can not be specified, as it depends on the number of treatments the subject may receive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - time to maximum concentration (tmax)</measure>
    <time_frame>For Cohorts 1, 2 and 3: Multiple timepoints taken, begining at Day 1 and until 30 days after last dose.</time_frame>
    <description>The total duration of this time frame can not be specified, as it depends on the number of treatments the subject may receive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, - terminal elimination rate constant (Î»z)</measure>
    <time_frame>For Cohorts 1, 2 and 3: Multiple timepoints taken, begining at Day 1 and until 30 days after last dose.</time_frame>
    <description>The total duration of this time frame can not be specified, as it depends on the number of treatments the subject may receive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - (AUC(0-t))</measure>
    <time_frame>For Cohorts 1, 2 and 3: Multiple timepoints taken, begining at Day 1 and until 30 days after last dose.</time_frame>
    <description>The total duration of this time frame can not be specified, as it depends on the number of treatments the subject may receive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - total clearance and terminal phase (Vz) of MEDI-573</measure>
    <time_frame>For Cohorts 1, 2 and 3: Multiple timepoints taken, begining at Day 1 and until 30 days after last dose.</time_frame>
    <description>The total duration of this time frame can not be specified, as it depends on the number of treatments the subject may receive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: - Insulin-like growth factor (IGF)-I and IGF-II on circulating plasma levels of MEDI-573</measure>
    <time_frame>For Cohorts 1, 2 and 3: Multiple timepoints taken, begining at Day 1 and until 30 days after last dose.</time_frame>
    <description>The total duration of this time frame can not be specified, as it depends on the number of treatments the subject may receive.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cancer</condition>
  <condition>Advanced Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>MEDI-573</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-573</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-573</intervention_name>
    <description>MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.</description>
    <arm_group_label>MEDI-573</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese men or women at least 20 years of age

          -  Histological or cytological confirmation of a solid, malignant tumour excluding
             lymphoma that is refractory to standard therapies or for which no standard therapies
             exist

          -  WHO performance status 0-2 with no deterioration over the previous 2 weeks

        Exclusion Criteria:

          -  Previous therapy with medication against IGF (ie, monoclonal antibodies with IGF-1R or
             IGF-targeting tyrosine kinase inhibitors)

          -  Inadequate bone marrow reserve or organ function

          -  Poorly controlled diabetes mellitus as defined by the investigator's assessment and/or
             glycosylated hemoglobin (HbA1c) reading &gt; 6.5% within 28 days prior to the first dose
             of MEDI-573

          -  History of allergy or reaction to any component of the MEDI-573 formulation or drugs
             with a similar chemical structure or class to MEDI-573
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Bradley, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=512&amp;filename=MEDI-573_D5621C00006_Protocol_Redacted_final.pdf</url>
    <description>Protocol Redacted</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2011</study_first_submitted>
  <study_first_submitted_qc>April 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2011</study_first_posted>
  <last_update_submitted>December 10, 2014</last_update_submitted>
  <last_update_submitted_qc>December 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>cancer</keyword>
  <keyword>solid tumours</keyword>
  <keyword>advanced solid malignancies</keyword>
  <keyword>dose escalation</keyword>
  <keyword>Insulin like growth factor</keyword>
  <keyword>Japanese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

